Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

FARP1 Facilitates Cell Proliferation Through Modulating MAPK Signaling Pathway in Cutaneous Melanoma

Chen, Zhao-Hui MB*; Wang, Li-Hua MD

The American Journal of Dermatopathology: December 2019 - Volume 41 - Issue 12 - p 908–913
doi: 10.1097/DAD.0000000000001426
Original Study

Purpose: The purpose of our study was to investigate the biological functions of FARP1 gene in cutaneous melanoma.

Methods: The mRNA expression level of FARP1 in cutaneous melanoma was analyzed based on the data obtained from ONCOMINE and The Cancer Genome Atlas database. Kaplan–Meier analysis was conducted to explore the association between FARP1 expression and the overall survival time of patients with cutaneous melanoma. The mRNA expression of FARP1 in melanoma cells was determined by qRT-PCR. A-375 cell line with silenced FARP1 was constructed to explore its biological functions. Cell proliferation, migration, and invasion abilities were determined by CCK8 assay, wound-healing assay, and transwell assays, respectively. Western blot was performed to explore the protein expression of FARP1, pMEK, MEK, pERK, and ERK.

Results: Our results showed that the expression level of FARP1 was upregulated in cutaneous melanoma tissues and cells. Kaplan–Meier analysis revealed that high expression of FARP1 is predictive of shorter overall survival time in patients with cutaneous melanoma. Through CCK8 assay, we found that knockdown of FARP1 in A-375 cells exhibited dramatically inhibitory effect on cell proliferation. The results of wound-healing and transwell assays revealed that the motility of A-375 cells was notably suppressed after silencing FARP1. Moreover, the relative expression levels of pMEK/MEK and pERK/ERK decreased remarkably in A-375 cells following being transfected with si-FARP1.

Conclusions: Our present results preliminary proofed that FARP1 possibly acts as a promoter in cutaneous melanoma development and possesses the potential to be a therapeutic target in patients with cutaneous melanoma.

*Department of Dermatological, Second Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China; and

Department of Dermatology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, People's Republic of China.

Correspondence: Li-Hua Wang, MD, Department of Dermatology, Jinan Central Hospital Affiliated to Shandong University, No. 105 Jiefang Road, Jinan, Shandong 250013, People's Republic of China (e-mail:

Z.-H. Chen and L.-H. Wang designed this work. Z.-H. Chen performed the experiments and wrote the manuscript. L.-H. Wang explained the results and revised the manuscript.

The authors declare no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.